Cingulate Inc. Reports $5.87 Million Net Loss and $28.4 Million Cash Reserves for Quarter Ended June 30, 2026

Cingulate Inc. reported significant financial developments in its latest 10-Q filing for the quarter ended June 30, 2026. The company recorded a net loss of $5.87 million for the quarter, compared to a loss of $4.98 million in the same period last year, marking a 17.8% increase in losses. For the six months ending June 30, 2026, the net loss was $15.18 million, up from $8.84 million in the prior year, reflecting a 71.8% increase. The company's operating expenses for the quarter were $5.41 million, a 16.5% increase from $4.65 million in the previous year, driven primarily by a 101.5% rise in selling, general, and administrative expenses, which reached $3.93 million.

In terms of operational changes, Cingulate's research and development expenses decreased by 44.9% to $1.49 million for the quarter, down from $2.70 million in the prior year. This decline was attributed to the conclusion of clinical study activities and the absence of regulatory costs associated with the New Drug Application (NDA) for CTx-1301, which was submitted in July 2025. The company is currently addressing a Complete Response Letter (CRL) received from the FDA in June 2026, which requested additional Chemistry, Manufacturing, and Controls (CMC) information for CTx-1301.

Cingulate's cash and cash equivalents increased significantly to approximately $28.4 million as of June 30, 2026, compared to $10.95 million at the end of 2025. This increase was primarily due to financing activities, including net proceeds of $31.05 million from the issuance of common stock and warrants during the first half of 2026. The company anticipates that its current cash reserves will be sufficient to fund operations into mid-2027, although it will require additional capital to support ongoing development and commercialization efforts.

The company has also made strategic moves to enhance its operational capabilities, including entering into a commercial distribution agreement with Prasco, LLC, to support the launch of CTx-1301, pending FDA approval. Additionally, Cingulate has engaged Indegene, Inc. for commercialization services, focusing on market access, medical education, and marketing strategies. The company is actively preparing for a potential launch, contingent upon successful resolution of the issues raised in the CRL.

Looking ahead, Cingulate remains focused on advancing its product candidates, particularly CTx-1301, while navigating the complexities of regulatory approval and market entry. The company acknowledges the inherent risks associated with its development pipeline and the need for ongoing capital to sustain its operations and growth initiatives.